TABLE 1.
Baseline characteristics of patients with cancer initiating treatment with an immune checkpoint inhibitor
| Patients, n | 3946 |
| Female sex | 49.0 (1934) |
| Age, years, median (quartile 1–3) | 67 (59–74) |
| Months since cancer diagnosis, median (quartile 1–3) | 16 (5–49) |
| Medical anticancer treatment | |
| PD‐1 inhibitor | 82.4 (3251) |
| PD‐L1 inhibitor | 8.3 (326) |
| CTLA4 inhibitor | 18.1 (715) |
| Double checkpoint inhibitor treatment | 8.8 (346) |
| Concomitant chemotherapy a | 6.7 (266) |
| Any previous medical anticancer treatment b | 79.1 (3120) |
| Khorana score level | |
| 0 | 36.0 (1421) |
| 1 | 34.6 (1366) |
| 2 | 19.6 (772) |
| 3 | 8.0 (315) |
| 4+ | 1.8 (72) |
| Khorana risk category | |
| Low risk (0) | 36.0 (1421) |
| Intermediate risk (1–2) | 54.2 (2138) |
| High risk (3+) | 9.8 (387) |
| Khorana guideline threshold | |
| 0–1 | 70.6 (2787) |
| 2+ | 29.4 (1159) |
| Khorana components | |
| Cancer type | |
| Stomach | 0.3 (12) |
| Pancreatic | 1.9 (74) |
| Lung | 39.1 (1543) |
| Lymphoma | 0.7 (27) |
| Gynecologic | 1.2 (48) |
| Bladder | 3.5 (137) |
| Testicular | n/a (<5) |
| Pre‐treatment laboratory values | |
| Hemoglobin level <10 g/dl or use of erythropoiesis stimulating agent | 8.7 (343) |
| Platelet count ≥ 350 x 109/L | 30.1 (1189) |
| Leukocyte count > 11 x 109/L | 16.4 (646) |
| Body mass index ≥ 35 kg/m2 | 1.1 (43) |
a
Patients registered with a treatment code for chemotherapy ±7 days in relation to date of checkpoint inhibitor treatment.
b
Defined as any anticancer treatment given >30 days prior to checkpoint inhibitor treatment.